{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T01:16:08Z","timestamp":1770513368431,"version":"3.49.0"},"reference-count":14,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2022,9,20]]},"DOI":"10.1001\/jama.2022.14663","type":"journal-article","created":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T15:03:20Z","timestamp":1663686200000},"page":"1049","source":"Crossref","is-referenced-by-count":10,"title":["Roflumilast for Chronic Plaque Psoriasis"],"prefix":"10.1001","volume":"328","author":[{"given":"Kelly M.","family":"Cordoro","sequence":"first","affiliation":[{"name":"Department of Dermatology, University of California, San Francisco"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"4","key":"jed220065r1","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.jaad.2018.11.058","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities.","volume":"80","author":"Elmets","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"jed220065r2","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.","volume":"80","author":"Menter","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"jed220065r3","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.jaad.2020.07.087","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures.","volume":"84","author":"Elmets","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"jed220065r4","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2022.15632","article-title":"Effect of roflumilast cream vs vehicle cream on chronic plaque psoriasis: the DERMIS-1 and DERMIS-2 randomized clinical trials.","author":"Lebwohl","year":"2022","journal-title":"JAMA"},{"issue":"1","key":"jed220065r5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3109\/09546634.2013.865009","article-title":"The 5-point Investigator\u2019s Global Assessment (IGA) Scale: a modified tool for evaluating plaque psoriasis severity in clinical trials.","volume":"26","author":"Langley","year":"2015","journal-title":"J Dermatolog Treat"},{"issue":"6","key":"jed220065r6","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.jaad.2003.09.014","article-title":"A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis.","volume":"50","author":"Carlin","year":"2004","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"jed220065r7","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/bjd.2016.175.issue-1","article-title":"Psychometric properties of the Itch Numeric Rating Scale in patients with moderate-to-severe plaque psoriasis.","volume":"175","author":"Kimball","year":"2016","journal-title":"Br J Dermatol"},{"issue":"6","key":"jed220065r8","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1111\/ijd.2014.53.issue-6","article-title":"The Psoriasis Symptom Diary: development and content validity of a novel patient-reported outcome instrument.","volume":"53","author":"Lebwohl","year":"2014","journal-title":"Int J Dermatol"},{"issue":"2","key":"jed220065r9","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1080\/09546634.2020.1789050","article-title":"Vehicles for atopic dermatitis therapies: more than just a placebo.","volume":"33","author":"Danby","year":"2022","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"jed220065r10","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1056\/NEJMoa2000073","article-title":"Trial of roflumilast cream for chronic plaque psoriasis.","volume":"383","author":"Lebwohl","year":"2020","journal-title":"N Engl J Med"},{"issue":"6","key":"jed220065r11","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1159\/000455840","article-title":"Psoriasis and obesity.","volume":"232","author":"Jensen","year":"2016","journal-title":"Dermatology"},{"key":"jed220065r12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.03.052","article-title":"Racial and ethnic disparities in clinical research and the dermatology workforce.","author":"Omar","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"jed220065r13","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1080\/09546634.2016.1181256","article-title":"Adherence in dermatology.","volume":"28","author":"Ahn","year":"2017","journal-title":"J Dermatolog Treat"},{"issue":"5","key":"jed220065r14","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1001\/jamadermatol.2021.0356","article-title":"Use of active comparator trials for topical medications in dermatology.","volume":"157","author":"Miller","year":"2021","journal-title":"JAMA Dermatol"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2796397\/jama_cordoro_2022_ed_220065_1663338174.55685.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,19]],"date-time":"2023-02-19T18:13:47Z","timestamp":1676830427000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2796397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,20]]},"references-count":14,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,9,20]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2022.14663","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9,20]]}}}